Front Cell Neurosci. 2015 May 28;9:209. doi: 10.3389/fncel.2015.00209. eCollection 2015.

Lithium protects against paraquat neurotoxicity by NRF2 activation and miR-34a inhibition in SH-SY5Y cells.

Frontiers in cellular neuroscience

Begum Alural, Aysegul Ozerdem, Jens Allmer, Kursad Genc, Sermin Genc

PMID: 26074776 PMCID: PMC4446540 DOI: 10.3389/fncel.2015.00209

Abstract

Lithium is a mood stabilizing agent commonly used for the treatment of bipolar disorder. Here, we investigated the potential neuroprotective effect of lithium against paraquat toxicity and its underlying mechanisms in vitro. SH-SY5Y human neuroblastoma cells were treated with paraquat (PQ) 0.5 mM concentration after lithium pretreatment to test lithium's capability in preventing cell toxicity. Cell death was evaluated by LDH, WST-8, and tryphan blue assays. Apoptosis was analyzed using DNA fragmentation, Annexin V immunostaining, Sub G1 cell cycle analysis, and caspase-3 activity assays. BCL2, BAX, and NRF2 protein expression were evaluated by Western-blotting and the BDNF protein level was determined with ELISA. mRNA levels of BCL2, BAX, BDNF, and NRF2 target genes (HO-1, GCS, NQO1), as well as miR-34a expression were analyzed by qPCR assay. Functional experiments were done via transfection with NRF2 siRNA and miR-34a mimic. Lithium treatment prevented paraquat induced cell death and apoptosis. Lithium treated cells showed increased anti-apoptotic protein BCL2 and decreased pro-apoptotic protein BAX expression. Lithium exerted a neurotrophic effect by increasing BDNF protein expression. It also diminished reactive oxygen species production and activated the redox sensitive transcription factor NRF2 and increased its target genes expression. Knockdown of NRF2 abolished neuroprotective, anti-apoptotic, and anti-oxidant effects of lithium. Furthermore, lithium significantly decreased both basal and PQ-induced expression of miR-34a. Transfection of miR-34a specific mimic reversed neuroprotective, anti-apoptotic, and anti-oxidant effects of lithium against PQ-toxicity. Our results revealed two novel mechanisms of lithium neuroprotection, namely NRF2 activation and miR-34a suppression.

Keywords: NRF2; Parkinson's disease; bipolar disorder; lithium; miR-34a

References

1. Cell Death Differ. 2010 Jul;17(7):1115-25 - PubMed
2. Neural Regen Res. 2013 Jul 25;8(21):2003-14 - PubMed
3. Methods Mol Biol. 2014;1107:15-31 - PubMed
4. J Parkinsons Dis. 2013;3(1):1-11 - PubMed
5. Methods Mol Biol. 2011;694:49-61 - PubMed
6. Toxicol Lett. 2014 Aug 4;228(3):179-91 - PubMed
7. Toxicol Lett. 2010 Dec 15;199(3):239-46 - PubMed
8. Nat Rev Neurol. 2013 Jun;9(6):328-39 - PubMed
9. Neuropsychopharmacology. 2009 May;34(6):1395-405 - PubMed
10. Oncotarget. 2014 Feb 28;5(4):872-81 - PubMed
11. J Cell Sci. 2012 Jan 1;125(Pt 1):7-17 - PubMed
12. Behav Pharmacol. 2010 Sep;21(5-6):473-92 - PubMed
13. J Am Soc Nephrol. 2011 Jul;22(7):1252-61 - PubMed
14. Bipolar Disord. 2015 May;17(3):278-90 - PubMed
15. Neurochem Res. 2009 Mar;34(3):453-62 - PubMed
16. Cell Signal. 2013 Oct;25(10):1939-48 - PubMed
17. Biol Mood Anxiety Disord. 2012 Sep 12;2:15 - PubMed
18. Free Radic Res. 2014 Jun;48(6):623-40 - PubMed
19. Psychopharmacology (Berl). 2001 Oct;158(1):100-6 - PubMed
20. Brain Res. 2015 Sep 24;1621:239-51 - PubMed
21. Front Cell Neurosci. 2014 Jun 10;8:156 - PubMed
22. Biol Trace Elem Res. 2014 Jun;159(1-3):410-5 - PubMed
23. J Toxicol. 2013;2013:347312 - PubMed
24. Neuropharmacology. 2002 Dec;43(7):1173-9 - PubMed
25. Antioxid Redox Signal. 2009 Sep;11(9):2105-18 - PubMed
26. Toxicology. 2013 May 10;307:24-34 - PubMed
27. Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2933-8 - PubMed
28. Int J Neuropsychopharmacol. 2009 Aug;12(7):975-81 - PubMed
29. Oxid Med Cell Longev. 2014;2014:590808 - PubMed
30. Genome Res. 2007 Dec;17(12):1850-64 - PubMed
31. Nat Genet. 2007 Oct;39(10):1278-84 - PubMed
32. Neurobiol Dis. 2004 Feb;15(1):160-70 - PubMed
33. Annu Rev Pharmacol Toxicol. 2014;54:141-64 - PubMed
34. CNS Neurosci Ther. 2012 Mar;18(3):201-7 - PubMed
35. Biochim Biophys Acta. 2014 Aug;1842(8):1208-18 - PubMed
36. Nucleic Acids Res. 2011 Sep 1;39(16):6845-53 - PubMed
37. Cell. 1993 Dec 3;75(5):843-54 - PubMed
38. Nucleic Acids Res. 2013 Jan;41(Database issue):D48-55 - PubMed
39. CNS Drugs. 2013 Feb;27(2):135-53 - PubMed
40. Pharmacol Rev. 2013 Jan 08;65(1):105-42 - PubMed
41. J Neuroimmune Pharmacol. 2013 Mar;8(1):189-201 - PubMed
42. Hum Mol Genet. 2011 Aug 1;20(15):3067-78 - PubMed
43. Gene. 2013 Dec 10;532(1):18-23 - PubMed
44. Free Radic Biol Med. 2014 Jan;66:36-44 - PubMed
45. Neurosci Lett. 2011 Sep 20;502(3):186-91 - PubMed
46. Prog Neurobiol. 2014 Jan;112:24-49 - PubMed
47. Cell Mol Life Sci. 2014 Jun;71(12):2253-70 - PubMed
48. Brain Res Bull. 2009 Oct 28;80(4-5):268-73 - PubMed
49. Exp Neurol. 2015 Jun;268:46-53 - PubMed
50. J Biol Chem. 2011 Nov 25;286(47):41125-34 - PubMed
51. Mol Psychiatry. 2015 May;20(5):573-84 - PubMed
52. J Parkinsons Dis. 2013;3(4):461-91 - PubMed
53. Int J Neuropsychopharmacol. 2014 Dec 28;18(6):null - PubMed
54. Toxicol Lett. 2014 Oct 15;230(2):85-103 - PubMed
55. Oxid Med Cell Longev. 2013;2013:836760 - PubMed
56. Cell. 2006 Sep 22;126(6):1203-17 - PubMed
57. Parkinsons Dis. 2011 Jan 18;2011:487450 - PubMed
58. Neuropsychiatr Dis Treat. 2013;9:493-500 - PubMed
59. Pharmacol Ther. 2013 May;138(2):155-75 - PubMed
60. ACS Chem Neurosci. 2014 Jun 18;5(6):443-50 - PubMed
61. Am J Transl Res. 2013 May 24;5(4):450-64 - PubMed
62. J Biomed Biotechnol. 2012;2012:845618 - PubMed
63. Nutrients. 2014 Sep 19;6(9):3777-801 - PubMed
64. Prog Neurobiol. 2013 Jul-Aug;106-107:17-32 - PubMed
65. Prog Neuropsychopharmacol Biol Psychiatry. 2012 Aug 7;38(2):183-9 - PubMed
66. Neurology. 2015 Feb 17;84(7):645-53 - PubMed
67. J Biosci. 2006 Sep;31(3):423-34 - PubMed
68. Nucleic Acids Res. 2011 Jan;39(Database issue):D163-9 - PubMed
69. J Toxicol Environ Health A. 2008;71(4):289-99 - PubMed

Publication Types

• Journal Article